Neutralization mechanism of human monoclonal antibodies against Rift Valley fever virus

Qihui Wang, Tong Ma, Yan Wu, Zhihai Chen, Hui Zeng, Zhou Tong, Feng Gao, Jianxun Qi, Zhennan Zhao, Yan Chai, Huabing Yang, Gary Wong, Yuhai Bi, Lili Wu, Rui Shi, Mi Yang, Jian Song, Haihai Jiang, Zhiqiang An, Junzhi WangTilahun Yilma, Yi Shi, William J. Liu, Mifang Liang, Chuan Qin, George F. Gao, Jinghua Yan

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Rift Valley fever virus (RVFV) is a mosquito-borne pathogen that causes substantial morbidity and mortality in livestock and humans. To date, there are no licensed human vaccines or therapeutics available. Here, we report the isolation of monoclonal antibodies from a convalescent patient, targeting the RVFV envelope proteins Gn and Gc. The Gn-specific monoclonal antibodies exhibited much higher neutralizing activities in vitro and protection efficacies in mice against RVFV infection, compared to the Gc-specific monoclonal antibodies. The Gn monoclonal antibodies were found to interfere with soluble Gn binding to cells and prevent infection by blocking the attachment of virions to host cells. Structural analysis of Gn complexed with four Gn-specific monoclonal antibodies resulted in the definition of three antigenic patches (A, B and C) on Gn domain I. Both patches A and B are major neutralizing epitopes. Our results highlight the potential of antibody-based therapeutics and provide a structure-based rationale for designing vaccines against RVFV.

Original languageEnglish (US)
JournalNature Microbiology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Rift Valley fever virus
Monoclonal Antibodies
Vaccines
Viral Envelope Proteins
Livestock
Virus Diseases
Culicidae
Virion
Epitopes
Morbidity
Mortality
Antibodies
Therapeutics
Infection

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Applied Microbiology and Biotechnology
  • Genetics
  • Microbiology (medical)
  • Cell Biology

Cite this

Neutralization mechanism of human monoclonal antibodies against Rift Valley fever virus. / Wang, Qihui; Ma, Tong; Wu, Yan; Chen, Zhihai; Zeng, Hui; Tong, Zhou; Gao, Feng; Qi, Jianxun; Zhao, Zhennan; Chai, Yan; Yang, Huabing; Wong, Gary; Bi, Yuhai; Wu, Lili; Shi, Rui; Yang, Mi; Song, Jian; Jiang, Haihai; An, Zhiqiang; Wang, Junzhi; Yilma, Tilahun; Shi, Yi; Liu, William J.; Liang, Mifang; Qin, Chuan; Gao, George F.; Yan, Jinghua.

In: Nature Microbiology, 01.01.2019.

Research output: Contribution to journalArticle

Wang, Q, Ma, T, Wu, Y, Chen, Z, Zeng, H, Tong, Z, Gao, F, Qi, J, Zhao, Z, Chai, Y, Yang, H, Wong, G, Bi, Y, Wu, L, Shi, R, Yang, M, Song, J, Jiang, H, An, Z, Wang, J, Yilma, T, Shi, Y, Liu, WJ, Liang, M, Qin, C, Gao, GF & Yan, J 2019, 'Neutralization mechanism of human monoclonal antibodies against Rift Valley fever virus', Nature Microbiology. https://doi.org/10.1038/s41564-019-0411-z
Wang, Qihui ; Ma, Tong ; Wu, Yan ; Chen, Zhihai ; Zeng, Hui ; Tong, Zhou ; Gao, Feng ; Qi, Jianxun ; Zhao, Zhennan ; Chai, Yan ; Yang, Huabing ; Wong, Gary ; Bi, Yuhai ; Wu, Lili ; Shi, Rui ; Yang, Mi ; Song, Jian ; Jiang, Haihai ; An, Zhiqiang ; Wang, Junzhi ; Yilma, Tilahun ; Shi, Yi ; Liu, William J. ; Liang, Mifang ; Qin, Chuan ; Gao, George F. ; Yan, Jinghua. / Neutralization mechanism of human monoclonal antibodies against Rift Valley fever virus. In: Nature Microbiology. 2019.
@article{002ee843d9e8413388b9ce3b9a13085f,
title = "Neutralization mechanism of human monoclonal antibodies against Rift Valley fever virus",
abstract = "Rift Valley fever virus (RVFV) is a mosquito-borne pathogen that causes substantial morbidity and mortality in livestock and humans. To date, there are no licensed human vaccines or therapeutics available. Here, we report the isolation of monoclonal antibodies from a convalescent patient, targeting the RVFV envelope proteins Gn and Gc. The Gn-specific monoclonal antibodies exhibited much higher neutralizing activities in vitro and protection efficacies in mice against RVFV infection, compared to the Gc-specific monoclonal antibodies. The Gn monoclonal antibodies were found to interfere with soluble Gn binding to cells and prevent infection by blocking the attachment of virions to host cells. Structural analysis of Gn complexed with four Gn-specific monoclonal antibodies resulted in the definition of three antigenic patches (A, B and C) on Gn domain I. Both patches A and B are major neutralizing epitopes. Our results highlight the potential of antibody-based therapeutics and provide a structure-based rationale for designing vaccines against RVFV.",
author = "Qihui Wang and Tong Ma and Yan Wu and Zhihai Chen and Hui Zeng and Zhou Tong and Feng Gao and Jianxun Qi and Zhennan Zhao and Yan Chai and Huabing Yang and Gary Wong and Yuhai Bi and Lili Wu and Rui Shi and Mi Yang and Jian Song and Haihai Jiang and Zhiqiang An and Junzhi Wang and Tilahun Yilma and Yi Shi and Liu, {William J.} and Mifang Liang and Chuan Qin and Gao, {George F.} and Jinghua Yan",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41564-019-0411-z",
language = "English (US)",
journal = "Nature Microbiology",
issn = "2058-5276",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Neutralization mechanism of human monoclonal antibodies against Rift Valley fever virus

AU - Wang, Qihui

AU - Ma, Tong

AU - Wu, Yan

AU - Chen, Zhihai

AU - Zeng, Hui

AU - Tong, Zhou

AU - Gao, Feng

AU - Qi, Jianxun

AU - Zhao, Zhennan

AU - Chai, Yan

AU - Yang, Huabing

AU - Wong, Gary

AU - Bi, Yuhai

AU - Wu, Lili

AU - Shi, Rui

AU - Yang, Mi

AU - Song, Jian

AU - Jiang, Haihai

AU - An, Zhiqiang

AU - Wang, Junzhi

AU - Yilma, Tilahun

AU - Shi, Yi

AU - Liu, William J.

AU - Liang, Mifang

AU - Qin, Chuan

AU - Gao, George F.

AU - Yan, Jinghua

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Rift Valley fever virus (RVFV) is a mosquito-borne pathogen that causes substantial morbidity and mortality in livestock and humans. To date, there are no licensed human vaccines or therapeutics available. Here, we report the isolation of monoclonal antibodies from a convalescent patient, targeting the RVFV envelope proteins Gn and Gc. The Gn-specific monoclonal antibodies exhibited much higher neutralizing activities in vitro and protection efficacies in mice against RVFV infection, compared to the Gc-specific monoclonal antibodies. The Gn monoclonal antibodies were found to interfere with soluble Gn binding to cells and prevent infection by blocking the attachment of virions to host cells. Structural analysis of Gn complexed with four Gn-specific monoclonal antibodies resulted in the definition of three antigenic patches (A, B and C) on Gn domain I. Both patches A and B are major neutralizing epitopes. Our results highlight the potential of antibody-based therapeutics and provide a structure-based rationale for designing vaccines against RVFV.

AB - Rift Valley fever virus (RVFV) is a mosquito-borne pathogen that causes substantial morbidity and mortality in livestock and humans. To date, there are no licensed human vaccines or therapeutics available. Here, we report the isolation of monoclonal antibodies from a convalescent patient, targeting the RVFV envelope proteins Gn and Gc. The Gn-specific monoclonal antibodies exhibited much higher neutralizing activities in vitro and protection efficacies in mice against RVFV infection, compared to the Gc-specific monoclonal antibodies. The Gn monoclonal antibodies were found to interfere with soluble Gn binding to cells and prevent infection by blocking the attachment of virions to host cells. Structural analysis of Gn complexed with four Gn-specific monoclonal antibodies resulted in the definition of three antigenic patches (A, B and C) on Gn domain I. Both patches A and B are major neutralizing epitopes. Our results highlight the potential of antibody-based therapeutics and provide a structure-based rationale for designing vaccines against RVFV.

UR - http://www.scopus.com/inward/record.url?scp=85063809611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063809611&partnerID=8YFLogxK

U2 - 10.1038/s41564-019-0411-z

DO - 10.1038/s41564-019-0411-z

M3 - Article

C2 - 30936489

AN - SCOPUS:85063809611

JO - Nature Microbiology

JF - Nature Microbiology

SN - 2058-5276

ER -